Marksans Pharma FY25 PAT up 21% at Rs. 382.6 Cr

Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24

Rising Pharma gets final approval from USFDA for Mesalamine Suppositories 1000 mg

The approved product, Mesalamine Suppositories 1000 mg, has an estimated U.S. market size of US$ 29 million

Nureca’s manufacturing subsidiary secures USFDA registration

This registration authorizes Nureca Technologies to continue manufacturing and exporting asuite of medical devices to the United States

Glenmark receives ANDA approval for Olopatadine Hydrochloride ophthalmic solution USP, 0.2%

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the US by Glenmark Therapeutics, USA.

OneSource Specialty Pharma strengthens its board by appointing new directors

These appointments align with the group’s philosophy of having a strong and independent board with exceptional industry experts, ensuring strategic guidance and effective governance

Zota Health Care launched B2C online portal ‘davaindia’

This e-commerce platform is launched as a hyperlocal model

Mankind Pharma Q3 FY25 PAT dips 16% to Rs. 385 Cr

Q3 FY25 revenue up 24% to Rs 3,230 crore

Strides receives USFDA approval for Acetaminophen and Ibuprofen Tablets

The Acetaminophen and Ibuprofen tablets will be manufactured at the company’s flagship facility in KRSG, Bengaluru

Abbott India appoints Prithwish K Banerji as Commercial Director - Women’s Health, Metabolics and International Business

Prithwish has close to 28 years of experience in a Commercial role

Dr. Morepen introduces ‘LightLife’ to long-lasting weight management